Evidence map›Paper›PMID 29278882›Full record

ArticleCancer biomarkers : section A of Disease markers2018

Serine/arginine rich splicing factor 2 expression and clinic pathological features indicating a prognostic factor in human hepatocellular carcinoma patients.

Pingan Wang, Lingyu Guo, Kaipeng Li, Shanglei Ning, Weichen Shi, Zhaochen Liu, Yuxin Chen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer biomarkers : section A of Disease markers, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.1field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. RNA splicing: a dual-edged sword for hepatocellular carcinoma.Medical oncology (Northwood, London, England) · 2022
    Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Pingan WangDepartment of General Surgery, Qilu Hospital Affiliated to Shandong University, Jinan, Shandong, China.
Lingyu GuoDepartment of General Surgery, Qilu Hospital Affiliated to Shandong University, Jinan, Shandong, China.
Kaipeng LiDepartment of General Surgery, Qilu Hospital Affiliated to Shandong University, Jinan, Shandong, China.
Shanglei NingDepartment of General Surgery, Qilu Hospital Affiliated to Shandong University, Jinan, Shandong, China.
Weichen ShiDepartment of Breast Surgery, Qianfoshan Hospital Affiliated to Shandong University, Jinan, Shandong, China.
Zhaochen LiuDepartment of General Surgery, Qilu Hospital Affiliated to Shandong University, Jinan, Shandong, China.
Yuxin ChenDepartment of General Surgery, Qilu Hospital Affiliated to Shandong University, Jinan, Shandong, China.
Qilu Hospital of Shandong University · CNShandong Provincial QianFoShan Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis research was aimed to study the expression of Serine/arginine rich splicing factor 2 (SRSF2) in tissues of hepatocellular carcinoma, and explore the relationship between the expression and the clinic pathological and prognosis of human hepatocellular carcinoma (HCC).

methodsOne hundred and fifty-three pairs HCC tissues and adjacent normal tissue were collected from January 2010 to March 2013. The expression of SRSF2 gene was detected by immunohistochemistry, western blotting and real-time quantitative polymerase chain reaction (PCR), and the relationship between the expression and the clinic pathological and prognosis of HCC being analyzed.

resultsIn 153 cases of hepatocellular carcinoma, SRSF2 was highly expressed in 93 cases, low expression of 60 cases, immunohistochemistry score (6.50 ± 2.82), which was significantly higher than that in adjacent normal tissues (2.94 ± 1.23) (P< 0.05). The expression of SRSF2 in HCC was not associated with gender (χ2= 0.014, P= 0.906), age (χ2= 0.007, P= 0.931), tumor size (χ2= 3.566, P= 0.059) and T stage (χ2= 2.708, P= 0.100), and was significantly correlated with tumor differentiation (χ2= 9.687, P= 0.007), lymph node metastasis (χ2= 4.827, P= 0.028), distal metastasis (χ2= 9.235, P= 0.002), tumor, node, metastasis (TNM) stage (χ2= 3.978, P= 0.046), portal vein invasion and serum alpha-fetoprotein (χ2= 14.919, P= 0.000). The expression of SRSF2 protein in hepatocellular carcinoma was positively correlated (r = 0.704, P< 0.05) with serum alpha-fetoprotein through Pearson analysis. The survival rates of SRSF2 overexpressing hepatocellular carcinoma were 74.19%, 44.09%, 26.88%, 24.73% and 21.51% at 1 year, 2 years, 3 years, 4 years and 5 years respectively, which were lower than those of SRSF2 low expression group (93.33%, 71.67%, 56.67%, 51.67% and 50.00%).

conclusionSRSF2 is highly expressed in hepatocellular carcinoma and its expression increases with the degree of tumor differentiation and TNM staging. It is related to lymph node metastasis and metastasis of tumor cells, and is positively related to serum alpha fetoprotein content, and affects the postoperative survival time of HCC patients.

Indexed as

AgedAged, 80 and overBiomarkers, TumorCarcinoma, HepatocellularFemaleGene ExpressionHumansImmunohistochemistryLiver NeoplasmsMaleMiddle AgedNeoplasm GradingNeoplasm StagingPrognosisSerine-Arginine Splicing FactorsSurvival AnalysisBiomarkers, TumorSerine-Arginine Splicing FactorsSRSF2 protein, humanclinical pathologyhepatocellular carcinomaimmunohistochemistrySRSF2

Identifiers

PMID29278882
PMCPMC13078295
OpenAlexW2779962189

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.